A national guide to separating state-licensed pharmacy access, federal compounding records, approved-drug information, and laboratory-research listings before comparing price.
US research listing snapshotCompare 7 current BPC-157 listingsExact-size public listings kept separate from clinics and pharmacies.↓A US peptide search can surface prescription drugs, compounded preparations, telehealth offers, and laboratory-research materials in one result set. Federal and state records answer different questions, so no single lookup validates every route.
Use this checklist to verify the local product, seller, and supply records before comparing price or availability.
For an online pharmacy claim, use FDA’s state-license directory to reach the relevant board database and match the business, address, and current license before comparing price.
Check FDA approval, shortage, outsourcing-facility, and bulk-substance records separately; a state pharmacy license does not make every product or compounding claim federally supported.
A laboratory-research listing is not a prescription pathway. Compare only like-for-like catalog rows and retain the research-only boundary, source date, shipping claim, and evidence-access label.
Each answer is tied to the local records below so you can see what is confirmed, what remains unknown, and where to recheck it. Open the primary sources ↓
No blanket answer is supportable. For an online pharmacy claim, use FDA’s state-license directory to reach the relevant board database and match the business, address, and current license before comparing price. In United States, begin with Drugs@FDA approved drug database from U.S. Food and Drug Administration; the product, seller, and supply route still need to resolve to the same current record.
No. In United States, the 78 us listings / 20 boards shown here are national laboratory-research catalog observations ordered by availability and public list price at a matched nominal size. They do not rank local pharmacies, clinics, prescription access, medical suitability, safety, or quality.
For United States, start with Drugs@FDA approved drug database from U.S. Food and Drug Administration, then open Locate a state-licensed online pharmacy from U.S. Food and Drug Administration. The records answer separate questions, so confirm each current entry instead of treating one match as proof of the seller, product, and route together.
Resolve the identity first, then use this country’s official product and seller records. A matching name never transfers approval, trial evidence, or seller authority.
FDA staff proposed not adding KPV free base or KPV acetate to the 503A Bulks List, but PCAC recommended inclusion after reported 8-6-1 votes on both reviewed form questions on July 23, 2026. The advice is nonbinding, does not immediately change the list, and is not FDA approval or a final determination. FDA also states that neither form is a component of an FDA-approved drug and that it found no published human administration study.
Primary identity sourceFDA briefing document for KPV-related bulk drug substancesU.S. Food and Drug Administration ↗BPC-157 is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗TB-500 is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗GHK-Cu is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the PubChem compound recordNational Library of Medicine, PubChem ↗Semax is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Melanotan II is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗MOTS-c is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗EGRIFTA WR is an FDA-licensed tesamorelin prescription product under BLA 022505, with an 11.6 mg presentation and a defined HIV-lipodystrophy indication. The 10 mg research listings tracked here are not EGRIFTA WR, do not share its label, and do not inherit its approval or supply chain.
Primary identity sourceCheck the FDA Purple Book product recordU.S. Food and Drug Administration ↗FDA states that AOD-9604 free base and acetate are not components of an approved drug. The largest oral obesity study failed to show a statistically significant weight-loss difference, and the 2024 advisory committee voted 0 to 12 on placing the two forms on the 503A Bulks List. A public 5 mg research vial listing is not an approved product or the historical oral trial formulation.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Ipamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Selank is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗VYLEESI is an FDA-approved bremelanotide prescription product under NDA 210557 with a 1.75 mg autoinjector presentation and product-specific label. The 10 mg PT-141 research listings tracked here are not VYLEESI and do not inherit its approval or regulated supply chain.
Primary identity sourceRead the current DailyMed drug labelNational Library of Medicine, DailyMed ↗CJC-1295 no DAC is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗CJC-1295 DAC is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Retatrutide is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceTRIUMPH-1 Phase 3 study - NCT05929066ClinicalTrials.gov ↗Mazdutide is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceGLORY-1 Phase 3 study - NCT05607680ClinicalTrials.gov ↗Ecnoglutide is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceSLIMMER Phase 3 study - NCT05813795ClinicalTrials.gov ↗Enicepatide is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceCT388-103 Phase 2 study - NCT06525935ClinicalTrials.gov ↗Eloralintide is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceEloralintide Phase 2 study - NCT06230523ClinicalTrials.gov ↗Cagrilintide is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceREDEFINE 1 Phase 3 study - NCT05567796ClinicalTrials.gov ↗Petrelintide is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceZUPREME-1 Phase 2 study - NCT06662539ClinicalTrials.gov ↗CagriSema is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceREDEFINE 1 Phase 3 study - NCT05567796ClinicalTrials.gov ↗MariTide is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourcePhase 2 dose-ranging study - NCT05669599ClinicalTrials.gov ↗Survodutide is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceSYNCHRONIZE-1 Phase 3 study - NCT06066515ClinicalTrials.gov ↗VK2735 is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceVENTURE injectable Phase 2 study - NCT06068946ClinicalTrials.gov ↗Pemvidutide is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceIMPACT Phase 2b MASH study - NCT05989711ClinicalTrials.gov ↗Amycretin / Zenagamtide is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceAMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414ClinicalTrials.gov ↗Tirzepatide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the United States. Verify the exact local records below.
Primary identity sourceCurrent ZEPBOUND prescribing informationNational Library of Medicine, DailyMed ↗FOUNDAYO received FDA approval on April 1, 2026 under NDA 220934 for a defined adult weight-management population. The approval belongs to the exact tablets, label, manufacturer, prescription product, and US supply record. It does not transfer to a powder, research listing, imported presentation, or online product using the orforglipron name.
Primary identity sourceCurrent FOUNDAYO prescribing informationNational Library of Medicine, DailyMed ↗WEGOVY is an FDA-approved semaglutide product under NDA 215256. Ozempic and Rybelsus are separate semaglutide products with separate applications, presentations, and labeled uses. The ingredient name alone does not establish which product, indication, dose form, prescription record, pharmacy route, or seller applies, and it does not transfer FDA approval to compounded or unapproved semaglutide.
Primary identity sourceCurrent WEGOVY prescribing informationNational Library of Medicine, DailyMed ↗DSIP / Emideltide is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗IGF-1 LR3 is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the PubChem substance recordNational Library of Medicine, PubChem ↗Kisspeptin-10 / KP-10 is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the PubChem compound recordNational Library of Medicine, PubChem ↗Melanotan I is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the current SCENESSE labelNational Library of Medicine, DailyMed ↗NAD+ is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the PubChem compound recordNational Library of Medicine, PubChem ↗Sermorelin is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA orphan-drug recordU.S. Food and Drug Administration ↗FDA stated in December 2024 that products containing Thymosin Alpha-1 are not approved in the United States. The advisory committee voted 4 to 17 against placing both reviewed forms on the 503A Bulks List, and FDA currently identifies potential immunogenicity, impurity, and API-characterization concerns. These records do not authenticate a seller listing or decide every state pharmacy question.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the United States. Verify the exact local records below.
Primary identity sourceCurrent EGRIFTA WR prescribing informationNational Library of Medicine, DailyMed ↗Liraglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the United States. Verify the exact local records below.
Primary identity sourceCurrent SAXENDA prescribing informationNational Library of Medicine, DailyMed ↗SCENESSE begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the United States. Verify the exact local records below.
Primary identity sourceCurrent SCENESSE prescribing informationNational Library of Medicine, DailyMed ↗VYLEESI begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the United States. Verify the exact local records below.
Primary identity sourceCurrent VYLEESI prescribing informationNational Library of Medicine, DailyMed ↗These listings are for laboratory research materials. They are not local clinics, pharmacies, or approved products for human use.
Rank rule. Price rank is availability-aware and stays fixed when you search or re-sort this view. Affiliate status never enters the calculation.
Compare two lowest in-stock rowsChecked July 28, 2026 at 4:47 PM UTC. Confirmed means the public source matched the published price and returned a reliable current availability signal. No row needs manual review. This does not verify vial contents or product quality.
Open source-check ledger| Price rank / supplier | 10 mg price | Price / mg | Public evidence | Shipping claim | Open listing |
|---|---|---|---|---|---|
01Pure Health PeptidesPrice and stock confirmed Jul 27In stock | $40.00Source confirmed | $4.00 | Public lot COA libraryAccess: Public link · Seller claim · Jul 27, 2026 | Free shipping over $175; lower-order rate at checkout | |
02Purgo LabsCurrent public batch reportIn stock | $44.99Source confirmed | $4.50 | Public batch reportsAccess: Public link · Seller claim · Jul 23, 2026 | Live UPS rate; free UPS 3 Day Select over $250 | |
03Pepta LabsFree US shipping claimedIn stock | $52.79Source confirmed | $5.28 | COA on requestAccess: On request · Seller claim · Jul 23, 2026 | Free US shipping claimed | |
04Prime PeptidesPublic report linkedIn stock | $60.00Source confirmed | $6.00 | Report displayedAccess: Public link · Seller claim · Jul 23, 2026 | $9.95 US; free over $150 | |
05Biotech PeptidesPublic size-specific documentsIn stock | $92.00Source confirmed | $9.20 | COA, LC, and MS imagesAccess: Public link · Seller claim · Jul 23, 2026 | Free USPS Priority over $200; lower-order rate not stated | |
06AminoCore ResearchPrice confirmed; stock not statedStatus not stated | $55.00Source confirmed | $5.50 | COA includedAccess: Included with order · Seller claim · Jul 23, 2026 | Free shipping claimed | |
07Core PeptidesPrice shown; stock label absentStatus not stated | $97.00Source confirmed | $9.70 | COA tab shownAccess: Public link · Seller claim · Jul 23, 2026 | Free over $200; lower-order rate at checkout |
Official sources are linked directly. Open them to confirm the current record; this page is a guide, not a substitute for the regulator.